1. SARS-CoV-2 identification and IgA antibodies in saliva: One sample two tests approach for diagnosis
- Author
-
Francesco Barbaro, Ada Aita, Assunta Farella, Paola Fioretto, Enrico Coccorullo, Filippo Navaglia, Roberto Vettor, Daniela Basso, Anna Maria Cattelan, Aurora Socal, Alice Stoppa, and Mario Plebani
- Subjects
0301 basic medicine ,Male ,Saliva ,Naso-pharyngeal swab ,Clinical Biochemistry ,Gastroenterology ,Biochemistry ,0302 clinical medicine ,Saliva collection ,COVID-19 Testing ,80 and over ,Aged, 80 and over ,Salivary IgA ,biology ,SARS-CoV-2 ,Adult ,Aged ,Betacoronavirus ,Coronavirus Infections ,Female ,Humans ,Immunoglobulin A ,Middle Aged ,Reference Standards ,Specimen Handling ,Clinical Laboratory Techniques ,General Medicine ,030220 oncology & carcinogenesis ,Antibody ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Disease duration ,Serum iga ,Article ,03 medical and health sciences ,stomatognathic system ,Internal medicine ,medicine ,Biochemistry, medical ,business.industry ,Biochemistry (medical) ,medicine.disease ,Pneumonia ,030104 developmental biology ,biology.protein ,business - Abstract
Highlights • Saliva is an eligible matrix for SARS-CoV-2 molecular detection and IgA measurement. • Saliva collection offers several advantages: safe, non-invasive and self-collection. • Positive molecular testing results were associated with disease duration. • The presence of salivary IgA was associated with pneumonia and CRP values., Aim This study aims to verify whether standardized saliva collection is suitable for SARS-CoV-2 molecular detection and IgA measurement. Methods 43 COVID-19 inpatients and 326 screening subjects underwent naso-pharyngeal (NP)-swab and saliva collection (Salivette). Inpatients also underwent repeated blood collections to evaluate inflammation and organs involvement. In all patients and subjects, SARS-CoV-2 (gene E) rRT-PCR was undertaken in saliva and NP-swabs. Salivary IgA and serum IgA, IgG, IgM were measured on inpatients’ samples. Results NP-swabs and saliva were both SARS-CoV-2 positive in 7 (16%) or both negative in 35 (82%) out of 43 patients successfully included in the study. NP-swabs and saliva results did not perfectly match in one patient (saliva positive, NP-swab negative). Positive molecular results were significantly associated with disease duration (p = 0.0049). 326/326 screening subjects were SARS-CoV-2 negative on both NP-swabs and saliva. Among the 27 saliva samples tested for IgA, 18 were IgA positive. Salivary IgA positivity was associated with pneumonia (p = 0.002) and CRP values (p = 0.0183), not with other clinical and molecular data, or with serum immunoglubulins. Conclusions A standardized saliva collection can be adopted to detect SARS-CoV-2 infection in alternative to NP-swabs. Preliminary data on salivary IgA support the use of saliva also for patient monitoring.
- Published
- 2020
- Full Text
- View/download PDF